We are excited to congratulate the Hong Kong Med-Tech Association (HKMTA) on their new name, reflecting a stronger focus on technology. Our President and Managing Director, Jennifer Che, along with Principal Pauli Wong, were thrilled to celebrate this significant milestone with the organization at the recent HKMHDIA Medical Fair Forum.

Pauli, the official IP Advisor to HKMTA, joined Jennifer, one of the keynote speakers at the event, who shared about the importance of a well-thought-out intellectual property strategy for healthcare inventions. Jennifer emphasized the challenges of protecting biomedical products that operate at the intersection of regulatory affairs, IP, trade secret, and data privacy, particularly in the complex, multijurisdictional landscape of the Greater Bay Area (GBA). The event fostered valuable discussions on navigating these complexities, reinforcing our commitment to helping innovators safeguard their groundbreaking ideas.

我們過去活動

Recommended Insights

BREAKING NEWS: New Pilot Program for Hong Kong Applicants to get Accelerated Patent Examination in the Chinese Patent Office Starting January 1, 2023

2023年1月4日
New year, new resolutions! The CNIPA has recently announced a pilot program that provides Hong Kong applicants the opportunity to expedite their patent applications filed in China. Starting 1 Jan 2023, Hong Kong permanent residents and entities legally registered in Hong Kong can request prioritized examination for their invention patent applications before the CNIPA. To […]

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

2022年9月21日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

2021年6月9日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 1: Delayed Examination

2024年1月25日
December 2023 appears to have been an exceptionally busy and fruitful month in the China patent space. Following the State Council’s approval of the long-awaited Patent Law Implementation Regulations (“Regulations”, similar to the CFR in the US) in November, the CNIPA finally made public the full text of the Regulations just before the arrival of […]
Top crossarrow-right